Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Faeth Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $326.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$326.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Faeth Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Vousden Karen H | Director | – | Sep 15, 2026 | 1 |
| Craver Josiah | PAO | – | Jul 23, 2026 | 2 |
| Parikh Anand Kiran | President and CEO | 817,699 | Jul 23, 2026 | 4 |
| Stephenson Brian C | Chief Financial Officer | 46,688Indirect | Jul 1, 2026 | 3 |
| Ramasastry Saira | Director | – | Jun 16, 2026 | 1 |
| Hahn Stephen M. | Director | 44,763 | Jun 16, 2026 | 1 |
| Donenberg Phillip B. | Director | – | Jun 12, 2026 | 3 |
| Holmen Bob | Director | 25,598 | Jun 12, 2026 | 1 |
| Gerry Christopher | President & PEO | – | Jun 12, 2026 | 1 |
| Cambrian BioPharma Inc | 10% Owner | 130,142 | Jun 1, 2026 | 3 |
| Peyer James | 10% Owner, Other: See remarks below | 130,142 | Jun 1, 2026 | 3 |
| Englander Israel A | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Millennium Management LLC | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Millennium Group Management LLC | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Ics Opportunities II LLC | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Ricks Thomas G | Director | 8,932 | May 23, 2025 | 0 |
| Ringo William R | Director | 23,399 | May 23, 2025 | 0 |
| Humer Kristian | Director | 8,932 | May 23, 2025 | 0 |
| Celebi John | PRESIDENT AND CEO | 105,862 | Feb 26, 2025 | 0 |
| van der Horst Edward | CHIEF SCIENTIFIC OFFICER | 59,794 | Feb 26, 2025 | 0 |
| Krebs Stephanie | Chief Business Officer | – | Feb 14, 2025 | 0 |
| Vojta Deneen | Director | 8,932 | Jun 13, 2024 | 0 |
| English Jessie | Director | 8,932 | Jun 13, 2024 | 0 |
| Colgan Erin | CHIEF FINANCIAL OFFICER | 67,462 | Feb 16, 2024 | 0 |
| Gallagher Patrick Stephen | Chief Business Officer | 34,130 | Sep 11, 2023 | 0 |
| Broder Samuel | Director | 8,932 | Jul 12, 2023 | 0 |
| Presight Sensei Co-Invest Fund, L.P. | Other: See Explanation of Responses | 0Indirect | Jun 2, 2023 | 0 |
| Apeiron Investment Group Ltd. | 10% Owner | 0Indirect | Jun 2, 2023 | 0 |
| Angermayer Christian | 10% Owner | 0Indirect | Jun 2, 2023 | 0 |
| Presight Co-Invest Management, L.L.C. | Other: See Explanation of Responses | 0Indirect | Jun 2, 2023 | 0 |
| Pierce Robert Hamilton | Chief R&D Officer | 21,000 | Sep 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 (view filing) | Feb 18, 2021 | 427 days | Peyer JamesDirector, 10% Owner | PPurchase | +752 | $19.75 | +$14.9K | 0.0%4.69M after | AmendedDuplicate filing |
| Apr 21, 2022 (view filing) | Mar 23, 2021 | 394 days | Peyer JamesDirector, 10% Owner | PPurchase | +9.50K | $14.34 | +$136.2K | +0.2%4.80M after | AmendedDuplicate filing |
| Jun 10, 2022 (view filing) | Mar 2 | 100 days | Cambrian BioPharma Inc10% Owner | PPurchase | +1.20K | $3.20 | +$3.85K | 0.0%5.23M after | Amended |
| Jun 10, 2022 (view filing) | Mar 2 | 100 days | Peyer JamesDirector, 10% Owner | PPurchase | +1.20K | $3.20 | +$3.85K | 0.0%5.23M after | AmendedDuplicate filing |
| Feb 27, 2023 (view filing)8:10 PM ET | Feb 23 | 4 days | Presight Sensei Co-Invest Fund, L.P. and 3 othersOther: See Explanation of Responses | PPurchase | +2.20K | $1.61 | +$3.54K | +0.1%2.49M after | 2 lots |
| Jun 2, 2023 (view filing)5:03 PM ET | Jun 1 | 1 day | Presight Sensei Co-Invest Fund, L.P. and 3 othersOther: See Explanation of Responses | SSale | −3.44M | $1.58 | −$5.44M | −100.0%0 after | 2 lots |
| Sep 13, 2023 (view filing) | Sep 11 | 2 days | Celebi JohnPresident and CEO | PPurchase | +500 | $0.85 | +$425 | +0.5%111.3K after | |
| Dec 8, 2025 (view filing) | Dec 4-5 | 4 days | Peyer James10% Owner, Other: See remarks below | SSale | −21.3K | $10.93 | −$232.7K | −11.7%161.4K after | 4 lots |
| Dec 8, 2025 (view filing) | Dec 4-5 | 4 days | Cambrian BioPharma Inc10% Owner | SSale | −21.3K | $10.93 | −$232.7K | −11.7%161.4K after | 4 lotsDuplicate filing |
| Dec 10, 2025 (view filing) | Dec 8-9 | 2 days | Peyer James10% Owner, Other: See remarks below | SSale | −6.61K | $8.25 | −$54.6K | −4.1%155.1K after | 4 lots |
| Dec 10, 2025 (view filing) | Dec 9 | 1 day | Cambrian BioPharma Inc10% Owner | SSale | −6.61K | $8.25 | −$54.6K | −4.1%155.1K after | 4 lots |
| May 15, 2026 (view filing)4:22 PM ET | Mar 26-30 | 50 daysLate | Englander Israel A and 3 others10% Owner | PPurchase | +30.6K | $26.75 | +$818.3K | +26.6%145.7K after | 11 lots |
| May 15, 2026 (view filing)4:22 PM ET | Mar 26-30 | 50 daysLate | Englander Israel A and 3 others10% Owner | SSale | −3.25K | $27.50 | −$89.4K | −2.2%145.7K after | 6 lots |
| May 15, 2026 (view filing)4:22 PM ET | Mar 31-Apr 1 | 45 daysLate | Englander Israel A and 3 others10% Owner | PPurchase | +12.2K | $31.37 | +$382.1K | +9.0%147.7K after | 10 lots |
| May 15, 2026 (view filing)4:22 PM ET | Mar 31-Apr 1 | 45 daysLate | Englander Israel A and 3 others10% Owner | SSale | −2.74K | $28.07 | −$76.9K | −1.8%147.7K after | 7 lots |
| May 15, 2026 (view filing)4:24 PM ET | Apr 2-7 | 43 daysLate | Englander Israel A and 3 others10% Owner | PPurchase | +4.21K | $33.54 | +$141.4K | +3.2%134.0K after | 5 lots |
| May 15, 2026 (view filing)4:24 PM ET | Apr 2-7 | 43 daysLate | Englander Israel A and 3 others10% Owner | SSale | −17.1K | $31.51 | −$538.1K | −11.3%134.0K after | 12 lots |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Peyer James10% Owner, Other: See remarks below | SSale | −25.0K | $20.02 | −$500.5K | −16.1%130.1K after | 2 lots |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Cambrian BioPharma Inc10% Owner | SSale | −25.0K | $20.02 | −$500.5K | −16.1%130.1K after | 2 lots |
| Jun 24, 2026 (view filing) | Jun 22-23 | 2 days | Stephenson Brian CChief Financial Officer | PPurchase | +17.4K | $23.31 | +$405.9K | New position17.4K after | 8 lots |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Parikh Anand KiranPresident and CEO | PPurchase | +2.81K | $19.76 | +$55.4K | +0.4%764.2K after | |
| Jun 26, 2026 (view filing) | Jun 24-26 | 2 days | Stephenson Brian CChief Financial Officer | PPurchase | +15.6K | $25.65 | +$401.3K | +89.8%33.1K after | 8 lots |
| Jul 1, 2026 (view filing)8:09 PM ET | Jun 29-Jul 1 | 2 days | Stephenson Brian CChief Financial Officer | PPurchase | +13.6K | $23.92 | +$326.1K | +41.2%46.7K after | 6 lots |